Background Bronchopulmonary dysplasia (BPD) is a major morbidity in premature infants,
and impaired angiogenesis is considered a major contributor to BPD. Early caffeine …

Background Caffeine therapy for apnea of prematurity reduces the incidence of
bronchopulmonary dysplasia (BPD) in premature neonates. Several mechanisms, including …

Background While additional oxygen supply is often required for the survival of very
premature infants in intensive care, this also brings an increasing risk of progressive lung …

Rodent pups exposed to hyperoxia develop lung changes similar to bronchopulmonary
dysplasia (BPD) in extremely premature infants. Oxidative stress from hyperoxia can injure …

Background: Caffeine is a commonly used drug for apnea of prematurity. It may, however,
also have a beneficial effect on bronchopulmonary dysplasia (BPD), which is the most …

Background Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in
premature infants and hyperoxia exposure is a major cause. In hyperoxic lung injury animal …

Caffeine is used to prevent bronchopulmonary dysplasia (BPD) in premature neonates.
Hyperoxia contributes to the development of BPD, inhibits cell proliferation and decreases …

Background: Caffeine is widely used to manage apnea of prematurity, and reduces the
incidence of bronchopulmonary dysplasia (BPD). Deregulated transforming growth factor …

Background. Preterm birth implies an array of respiratory diseases including apnea of
prematurity and bronchopulmonary dysplasia (BPD). Caffeine has been introduced to treat …

Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease that occurs during the
neonatal period and is commonly associated with prematurity. This condition results in a …